Tonix Pharmaceuticals
Update in progressTNXP (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Tonix Pharmaceuticals Holding Corp. is a fully integrated biopharmaceutical company focused on therapies for CNS disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. It markets TONMYA for fibromyalgia and Zembrace SymTouch and Tosymra for acute migraine in adults. Its pipeline includes TNX-102 SL, TNX-1300, TNX-1500, TNX-4800, TNX-2900, TNX-801, TNX-4200, TNX-4900, TNX-1700, and TNX-1800/1850. Founded 2007, based in Berkeley Heights, NJ.
Company score
- Sentiment
- 0.55
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.01
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.64
- Governance
- 0.26
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.25
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.40
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Seth Lederman M.D.
- Founded2007
- Employees142
- Websitewww.tonixpharma.com
Identifiers
- ISINUS8902608392
- FIGIBBG000LG8XM5
- CUSIP890260102
- CIK0001430306